| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
Over the last 12 months, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Actinium Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Actinium Pharmaceuticals, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $4,372 was made by SETH SANDESH (Chairman & CEO) on 2018‑12‑10.
| 2018-12-10 | SETH SANDESH | Chairman & CEO | 10,000 0.0095% | $0.44 | $4,372 | -37.73% | ||
| 2018-12-10 | O'Loughlin Steve | Principal Financial Officer | 10,000 0.0095% | $0.43 | $4,350 | -37.73% | ||
| 2018-11-19 | Ludwig Dale L. | Chief Scientific Officer | 10,000 0.01% | $0.45 | $4,499 | -31.63% | ||
| 2018-07-17 | SETH SANDESH | CEO | 10,000 0.0094% | $0.79 | $7,900 | -28.76% | ||
| 2018-06-15 | O'Loughlin Steve | Principal Financial Officer | 12,000 0.0109% | $0.50 | $6,000 | +14.08% | ||
| 2018-04-19 | SETH SANDESH | Chairman & CEO | 5,000 0.0045% | $0.38 | $1,900 | +50.20% | ||
| 2018-02-28 | Shetty Ajit | director | 22,730 0.0257% | $0.43 | $9,774 | +25.81% | ||
| 2017-08-02 | SETH SANDESH | Chairman & CEO | 33,333 0.0538% | $0.75 | $25,000 | -3.30% | ||
| 2017-08-02 | Ray Nitya G. | Executive Vice President | 10,000 0.0161% | $0.75 | $7,500 | -3.30% | ||
| 2017-06-15 | SETH SANDESH | Chairman and CEO | 7,500 0.013% | $1.16 | $8,725 | -45.53% | ||
| 2017-06-15 | Berger Mark Stanley | Chief Medical Officer | 5,000 0.0083% | $1.11 | $5,550 | -45.53% | ||
| 2017-06-15 | O'Loughlin Steve | Principal Financial Officer | 3,500 0.0061% | $1.17 | $4,095 | -45.53% | ||
| 2016-12-30 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.88 | $4,400 | +16.57% | ||
| 2016-12-12 | SETH SANDESH | Executive Chairman | 5,000 0.0104% | $0.98 | $4,900 | +5.15% | ||
| 2016-08-31 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 136,853 0.2928% | $1.83 | $251,118 | -34.31% | |
| 2016-08-30 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 56,074 0.1174% | $1.81 | $101,254 | -33.90% | |
| 2016-08-29 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.0529% | $1.72 | $42,875 | -28.89% | |
| 2016-08-26 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 25,000 0.052% | $1.70 | $42,620 | -29.07% | |
| 2016-08-16 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 5,029 0.0107% | $1.72 | $8,652 | -26.18% | |
| 2016-08-15 | Sale | Memorial Sloan-Kettering Cancer Center | 10 percent owner | 4,439 0.0093% | $1.72 | $7,635 | -25.87% |
| Memorial Sloan-Kettering Cancer Center | 10 percent owner | 4709561 15.0106% | $4.85M | 0 | 25 | |
| SETH SANDESH | Chairman & CEO | 153333 0.4887% | $157,932.99 | 10 | 0 | <0.0001% |
| DAVE KAUSHIK J | CEO and Interim CFO | 88500 0.2821% | $91,155.00 | 1 | 0 | <0.0001% |
| O'Loughlin Steve | Principal Financial Officer | 35500 0.1131% | $36,565.00 | 3 | 0 | <0.0001% |
| Shetty Ajit | director | 22730 0.0724% | $23,411.90 | 1 | 0 | +25.81% |
| Nicholson, C. David | director | 15000 0.0478% | $15,450.00 | 1 | 0 | <0.0001% |
| Ray Nitya G. | Executive Vice President | 10000 0.0319% | $10,300.00 | 1 | 0 | <0.0001% |
| Ludwig Dale L. | Chief Scientific Officer | 10000 0.0319% | $10,300.00 | 1 | 0 | <0.0001% |
| Berger Mark Stanley | Chief Medical Officer | 5000 0.0159% | $5,150.00 | 1 | 0 | <0.0001% |
| TRAVERSA SERGIO | director | 3000 0.0096% | $3,090.00 | 2 | 0 | <0.0001% |
| Steinhart Richard I | director | 2500 0.008% | $2,575.00 | 1 | 0 | <0.0001% |
| MAZANET ROSEMARY | director | 100 0.0003% | $103.00 | 1 | 0 |
$2,542,362 | 111 | 11.81% | $42.37M | |
$693,326 | 47 | -16.24% | $47.49M | |
$6,204,522 | 45 | 1.91% | $28.45M | |
$30,257,839 | 29 | -15.72% | $23.91M | |
Actinium Pharmaceuticals, Inc. (ATNM) | $241,165 | 22 | -16.72% | $32.32M |
$226,127 | 22 | -27.62% | $45.57M | |
$352,389 | 18 | 9.66% | $33.23M | |
$91,696,644 | 18 | -4.72% | $46.96M | |
$20,234,041 | 17 | 2.09% | $40.57M | |
$1,246,170 | 12 | 65.67% | $20.72M | |
$176,752 | 10 | -28.86% | $23.38M | |
$4,176,565 | 9 | 18.77% | $22.6M | |
$114,586 | 6 | -12.52% | $25.14M | |
$26,254,149 | 5 | 49.97% | $38.43M | |
$5,306,958 | 5 | 11.70% | $36.3M | |
$1,499,988 | 3 | 0.92% | $35.41M | |
$150,000 | 1 | 5.48% | $24.31M | |
$35,811 | 1 | -10.94% | $23.7M | |
$5,512,500 | 1 | -7.91% | $28.25M |
| Increased Positions | 22 | +28.95% | 583,760 | +11.28% |
| Decreased Positions | 28 | -36.84% | 322,519 | -6.23% |
| New Positions | 9 | New | 282,521 | New |
| Sold Out Positions | 8 | Sold Out | 173,636 | Sold Out |
| Total Postitions | 70 | -7.89% | 5M | +5.05% |
| Vanguard Group Inc | $1,897.00 | 4.47% | 1.38M | +12,703 | +0.93% | 2025-09-30 |
| Millennium Management Llc | $856.00 | 2.02% | 624,697 | -38,572 | -5.82% | 2025-09-30 |
| Acadian Asset Management Llc | $671.00 | 1.58% | 489,577 | -2,366 | -0.48% | 2025-09-30 |
| Blackrock, Inc. | $498.00 | 1.17% | 363,486 | -104,187 | -22.28% | 2025-09-30 |
| Geode Capital Management, Llc | $450.00 | 1.06% | 328,419 | -1,270 | -0.39% | 2025-09-30 |
| Renaissance Technologies Llc | $395.00 | 0.93% | 288,630 | +79,129 | +37.77% | 2025-09-30 |
| Two Sigma Investments, Lp | $321.00 | 0.76% | 234,293 | +187,748 | +403.37% | 2025-09-30 |
| Gagnon Securities Llc | $310.00 | 0.73% | 226,257 | -365 | -0.16% | 2025-09-30 |
| Two Sigma Advisers, Lp | $269.00 | 0.63% | 196,376 | +196,376 | New | 2025-09-30 |
| Citadel Advisors Llc | $173.00 | 0.41% | 126,615 | +71,609 | +130.18% | 2025-09-30 |